Trial Profile
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real world population of hormone receptor positive advanced breast cancer: A multicenter Italian experience
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Feb 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 01 Feb 2016 New trial record
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium